Cancer gene therapy: fringe or cutting edge? (original) (raw)

• Morin, P. J., Vogelstein, B. & Kinzler, K. W. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl Acad. Sci. USA 93, 7950–7954 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Nikitin, A. Y., Juarez-Perez, M. I., Li, S., Huang, L. & Lee, W. H. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/− mice. Proc. Natl Acad. Sci. USA 96, 3916–3921 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Demers, G. W. et al. A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth. Cancer Gene Ther. 5, 207–214 (1998).
  CAS PubMed Google Scholar
• Craig, C. et al. Effects of adenovirus-mediated p16 INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 16, 265–272 (1998).
  Article CAS PubMed Google Scholar
• Sumitomo, K., Shimizu, E., Shinohara, A., Yokota, J. & Sone, S. Activation of RB tumor suppressor protein and growth suppression of small cell lung carcinoma cells by reintroduction of p16 INK4A gene. Int. J. Oncol. 14, 1075–1080 (1999).
  CAS PubMed Google Scholar
• Tanaka, M. et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19, 5406–5412 (2000).
  Article CAS PubMed Google Scholar
• Minaguchi, T. et al. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res. 59, 6063–6067 (1999).
  CAS PubMed Google Scholar
• Sakurada, A. et al. Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. Int. J. Oncol. 15, 1069–1074 (1999).
  CAS PubMed Google Scholar
• Cheney, I. W. et al. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 58, 2331–2334 (1998).
  CAS PubMed Google Scholar
• Yang, C. T. et al. Adenovirus-mediated p14 ARF gene transfer in human mesothelioma cells. J. Natl Cancer Inst. 92, 636–641 (2000).
  Article CAS PubMed Google Scholar
• Roth, J. A. et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2, 985–991 (1996).First report of p53 delivery to cancer cells in humans. Expression of p53 and increased apoptosis in treated tumours was reported, with no evidence of toxicity. The retrovirus delivery system was not sufficiently efficient, but this paper proved the principle that delivery of p53 could kill cancer cells in vivo.
  Article CAS PubMed Google Scholar
• Seth, P. et al. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers. Cancer Gene Ther. 4, 383–390 (1997).
  CAS PubMed Google Scholar
• Holt, J. T. et al. Growth retardation and tumour inhibition by BRCA1. Nature Genet. 12, 298–302 (1996).
  Article CAS PubMed Google Scholar
• Shao, N., Chai, Y. L., Shyam, E., Reddy, P. & Rao, V. N. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 13, 1–7 (1996).
  CAS PubMed Google Scholar
• Tait, D. L. et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin. Cancer Res. 3, 1959–1968 (1997).
  CAS PubMed Google Scholar
• Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).
  Article CAS PubMed Google Scholar
• Kaplan, K. B. et al. A role for the adenomatous polyposis coli protein in chromosome segregation. Nature Cell Biol. 3, 429–432 (2001).
  Article CAS PubMed Google Scholar
• Fodde, R. et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nature Cell Biol. 3, 433–438 (2001).
  Article CAS PubMed Google Scholar
• Zhang, W. W. et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1, 5–13 (1994).
  PubMed Google Scholar
• Nishizaki, M. et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin. Cancer Res. 5, 1015–102 (1999).
  CAS PubMed Google Scholar
• Bouvet, M. et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58, 2288–2292 (1998).
  CAS PubMed Google Scholar
• Dameron, K. M., Volpert, O. V., Tainsky, M. A. & Bouck, N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb. Symp. Quant. Biol. 59, 483–489 (1994).First connection between p53 and angiogenesis: the discovery that p53 regulates expression of the production of thrombospondin, a protein purified by Bouck and co-workers in an early biological assay for factors that block angiogenesis.
  Article CAS PubMed Google Scholar
• Buckbinder, L. et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377, 646–649 (1995).
  Article CAS PubMed Google Scholar
• Mueller, H. Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell. Mol. Life Sci. 54, 1291–1298 (1998).
  Article CAS PubMed Google Scholar
• Swisher, S. G. et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl Cancer Inst. 91, 763–771 (1999).
  Article CAS PubMed Google Scholar
• Clayman, G. L., Frank, D. K., Bruso, P. A. & Goepfert, H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 5, 1715–1722 (1999).
  CAS PubMed Google Scholar
• Nemunaitis, J. et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18, 609–622 (2000).
  Article CAS PubMed Google Scholar
• Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).
  Article CAS PubMed Google Scholar
• Barrington, R. E. et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell Biol. 18, 85–92 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).One of a series of landmark papers from Druker and colleagues, showing the clinical effects of STI-571 (Gleevec) in clinical trials. First successful demonstration that small molecules that target oncogenes can have clinical benefit.
  Article CAS PubMed Google Scholar
• Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810–816 (1999).
  Article CAS PubMed Google Scholar
• Mendelsohn, J. & Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550–6565 (2000).
  Article CAS PubMed Google Scholar
• Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276–5281 (1986).Early description of the concept of suicide gene therapy, in which HSV-tk is expressed in cells using viral vectors, and cells and their uninfected neighbours are killed by the approved clinical prodrug, ganciclovir. This system has been the most widely used of all suicide gene-therapy protocols.
  CAS PubMed Google Scholar
• Crystal, R. G. et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther. 8, 985–1001 (1997).
  Article CAS PubMed Google Scholar
• Takayama, K. et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 60, 2169–2177 (2000).
  CAS PubMed Google Scholar
• Chen, Q. R., Kumar, D., Stass, S. A. & Mixson, A. J. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 59, 3308–3312 (1999).
  CAS PubMed Google Scholar
• Chen, C. T. et al. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum. Gene Ther. 11, 1983–1996 (2000).
  Article CAS PubMed Google Scholar
• Regulier, E. et al. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther. 8, 45–54 (2001).
  Article CAS PubMed Google Scholar
• Brand, K. et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinase-2 into the liver tissue. Cancer Res. 60, 5723–5730 (2000).
  CAS PubMed Google Scholar
• Rainov, N. G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389–2401 (2000).
  Article CAS PubMed Google Scholar
• Sandmair, A. M. et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11, 2197–2205 (2000).
  Article CAS PubMed Google Scholar
• Aghi, M., Kramm, C. M., Chou, T. C., Breakefield, X. O. & Chiocca, E. A. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl Cancer Inst. 90, 370–380 (1998).
  Article CAS PubMed Google Scholar
• Touraine, R. L., Vahanian, N., Ramsey, W. J. & Blaese, R. M. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. 9, 2385–2391 (1998).
  Article CAS PubMed Google Scholar
• Sakai, Y. et al. Gene therapy for hepatocellular carcinoma using two recombinant adenovirus vectors with α-fetoprotein promoter and Cre/lox P system. J. Virol. Methods 92, 5–17 (2001).
  Article CAS PubMed Google Scholar
• Kirn, D. H. & McCormick, F. Replicating viruses as selective cancer therapeutics. Mol. Med. Today 2, 519–527 (1996).
  Article CAS PubMed Google Scholar
• Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D. & Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938–943 (1995).First use of a recombinant conditionally replicating virus to treat human cancer. This HSV mutant cannot replicate in quiescent cells because a key enzyme involved in DNA synthesis has been deleted. This mutant virus kills brain tumour cells selectively, because normal cells cannot support replication.
  Article CAS PubMed Google Scholar
• Markert, J. M. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867–874 (2000).
  Article CAS PubMed Google Scholar
• Randazzo, B. P., Bhat, M. G., Kesari, S., Fraser, N. W. & Brown, S. M. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Invest. Dermatol. 108, 933–937 (1997).
  Article CAS PubMed Google Scholar
• MacKie, R. M., Stewart, B. & Brown, S. M. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357, 525–526 (2001).
  Article CAS PubMed Google Scholar
• Rampling, R. et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859–866 (2000).
  Article CAS PubMed Google Scholar
• Barker, D. D. & Berk, A. J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107–121 (1987).
  Article CAS PubMed Google Scholar
• Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373–376 (1996).First virus described for which replication depends on loss of p53. This adenovirus mutant grows selectively in tumour cells in which p53 is inactive, but also depends on other functions of tumour cells that are not fully understood for its efficient replication. In this paper, it was shown for the first time that a recombinant virus destroys human xenograft tumours in mouse models of cancer.
  Article CAS PubMed Google Scholar
• Dix, B. R., Edwards, S. J. & Braithwaite, A. W. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J. Virol. 75, 5443–5447 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Heise, C. C., Williams, A., Olesch, J. & Kirn, D. H. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 6, 499–504 (1999).
  Article CAS PubMed Google Scholar
• Goodrum, F. D. & Ornelles, D. A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72, 9479–9490 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M. & zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72, 9470–9478 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Turnell, A. S., Grand, R. J. A. & Gallimore, P. H. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73, 2074–2083 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Ries, S. J. et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nature Med. 6, 1128–1133 (2000).
  Article CAS PubMed Google Scholar
• Harada, J. N. & Berk, A. J. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73, 5333–5344 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Nemunaitis, J. et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289–298 (2001).
  Article CAS PubMed Google Scholar
• Khuri, F. R. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 6, 879–885 (2000).
  Article CAS PubMed Google Scholar
• Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Med. 6, 1134–1139 (2000).
  Article CAS PubMed Google Scholar
• Fueyo, J. et al. A mutant oncolytic adenovirus targeting the RB pathway produces anti-glioma effect in vivo. Oncogene 19, 2–12 (2000).A mutant adenovirus that cannot neutralize RB is shown to replicate selectively in cancer cells. This approach is similar to the approach of dl1520, ONYX-015. In this case, a small mutation was made to inactivate E1A's ability to neutralize RB, and other functions of E1A were left intact.
  Article CAS PubMed Google Scholar
• Doronin, K. et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147–6155 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Doronin, K. et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75, 3314–3324 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Nevins, J. R. Adenovirus E1A-dependent trans-activation of transcription. Semin. Cancer Biol. 1, 59–68 (1990).Description of E2F, the crucial transcription factor activity responsible for entry into S-phase of the cell cycle. This factor is misregulated in almost all cancers, and is also vital for adenovirus replication, through its effects on S-phase and on activation of the E2 region of the viral genome.
  CAS PubMed Google Scholar
• Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559–2563 (1997).
  CAS PubMed Google Scholar
• Yu, D. C. et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 61, 517–525 (2001).
  CAS PubMed Google Scholar
• Brunori, M., Malerba, M., Kashiwazaki, H. & Iggo, R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol. 75, 2857–2865 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Kurihara, T., Brough, D. E., Kovesdi, I. & Kufe, D. W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106, 763–771 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Hallenbeck, P. L. Chang, Y.-N. & Chiang, Y. L. Vectors for tissue-specific replication. US Patent 5,998,205 (1999).
• Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D. & Kim, J. H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323–1333 (1998).
  Article CAS PubMed Google Scholar
• Wildner, O. et al. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6, 57–62 (1999).
  Article CAS PubMed Google Scholar
• Aghi, M., Chou, T. C., Suling, K., Breakefield, X. O. & Chiocca, E. A. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 59, 3861–3865 (1999).
  CAS PubMed Google Scholar
• Raj, K., Ogston, P. & Beard, P. Virus-mediated killing of cells that lack p53 activity. Nature 412, 914–917 (2001).
  Article CAS PubMed Google Scholar
• Kirn, D., Martuza, R. L. & Zwiebel, J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nature Med. 7, 781–787 (2001).
  Article CAS PubMed Google Scholar
• Alemany, R., Suzuki, K. & Curiel, D. T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81, 2605–2609 (2000).
  Article CAS PubMed Google Scholar
• Bergelson, J. M. et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 72, 415–419 (1998).Identification of the cellular receptor for adenovirus, using an ingenious expression-cloning strategy. Identification of CAR has greatly increased our understanding of adenovirus infectivity and efficiency of vectors using adenoviruses to deliver genes or kill cells through replication.
  Article CAS PubMed PubMed Central Google Scholar
• Honda, T. et al. The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. Brain Res. Mol. Brain Res. 77, 19–28 (2000).
  Article CAS PubMed Google Scholar
• Fechner, H. et al. Expression of coxsackie adenovirus receptor and α-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6, 1520–1535 (1999).
  Article CAS PubMed Google Scholar
• Okegawa, T. et al. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res. 60, 5031–5036 (2000).
  CAS PubMed Google Scholar
• Li, Y. et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 59, 325–330 (1999).
  CAS PubMed Google Scholar
• Bewley, M. C., Springer, K., Zhang, Y. B., Freimuth, P. & Flanagan, J. M. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 286, 1579–1583 (1999).
  Article CAS PubMed Google Scholar
• Hoganson, D. K., Sosnowski, B. A., Pierce, G. F. & Doukas, J. Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol. Ther. 3, 105–112 (2001).
  Article CAS PubMed Google Scholar
• Cripe, T. P. et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61, 2953–2960 (2001).A good example of retargeting adenovirus to infect cells through non-CAR-mediated interactions. These approaches are designed to overcome the fact that many cancer cells downregulate CAR expression, whereas CAR is abundantly expressed in many normal epithelial cells.
  CAS PubMed Google Scholar
• Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G. & Lieber, A. Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector. J. Virol. 74, 2567–2583 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Fisher, K. D. et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341–348 (2001).
  Article CAS PubMed Google Scholar
• Ikeda, K. et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Med. 5, 881–887 (1999).
  Article CAS PubMed Google Scholar
• Chen, Y., Yu, D. C., Charlton, D. & Henderson, D. R. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum. Gene Ther. 11, 1553–1567 (2000).
  Article CAS PubMed Google Scholar
• McCormick, F. New-age drug meets resistance. Nature 412, 281–282 (2001).
  Article CAS PubMed Google Scholar
• Grim, J. et al. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemo-resistance to cisplatin and paclitaxel. Clin. Cancer Res. 3, 2415–2423 (1997).
  CAS PubMed Google Scholar
• Patel, S. D. et al. The p53-independent tumoricidal activity of an adenoviral vector encoding a p27–p16 fusion tumor suppressor gene. Mol. Ther. 2, 161–169 (2000).
  Article CAS PubMed Google Scholar
• Riley, D. J., Nikitin, A. Y. & Lee, W. H. Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/− mice. Nature Med. 2, 1316–1321 (1996).
  Article CAS PubMed Google Scholar
• Claudio, P. P. et al. RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. Cancer Res. 61, 462–468 (2001).
  CAS PubMed Google Scholar
• Kawabe, S. et al. Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts. Int. J. Radiat. Biol. 77, 185–194 (2001).
  Article CAS PubMed Google Scholar
• Nielsen, L. L. et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4, 129–138 (1997).
  CAS PubMed Google Scholar
• Kataoka, M. et al. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res. 58, 4761–4765 (1998).
  CAS PubMed Google Scholar
• Spitz, F. R. et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 16, 3415–3422 (1996).
  CAS PubMed Google Scholar
• Czubayko, F. et al. Adenovirus-mediated transduction of ribozymes abrogates HER2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther. 4, 943–949 (1997).
  Article CAS PubMed Google Scholar
• Lui, V. W., He, Y. & Huang, L. Specific down-regulation of HER2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol. Ther. 3, 169–177 (2001).
  Article CAS PubMed Google Scholar
• Suzuki, T. et al. Adenovirus-mediated ribozyme targeting of HER2/neu inhibits in vivo growth of breast cancer cells. Gene Ther. 7, 241–248 (2000).
  Article CAS PubMed Google Scholar
• Tang, C. K. et al. Ribozyme-mediated down-regulation of ErbB4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. 59, 5315–5322 (1999).
  CAS PubMed Google Scholar
• Alemany, R. et al. Growth inhibitory effect of anti-KRAS adenovirus on lung cancer cells. Cancer Gene Ther. 3, 296–301 (1996).
  CAS PubMed Google Scholar
• Tsuchida, T. et al. Adenovirus-mediated anti-KRAS ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther. 7, 373–383 (2000).
  Article CAS PubMed Google Scholar
• Funato, T., Ishii, T., Kambe, M., Scanlon, K. J. & Sasaki, T. Anti-KRAS ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. Cancer Gene Ther. 7, 495–500 (2000).
  Article CAS PubMed Google Scholar
• Zhang, Y. A., Nemunaitis, J., Scanlon, K. J. & Tong, A. W. Anti-tumorigenic effect of a KRAS ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther. 7, 2041–2050 (2000).
  Article CAS PubMed Google Scholar
• Irie, A. et al. Therapeutic efficacy of an adenovirus-mediated anti-HRAS ribozyme in experimental bladder cancer. Antisense Nucleic Acid Drug Dev. 9, 341–349 (1999).
  Article CAS PubMed Google Scholar
• Kunke, D. et al. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Ther. 7, 766–777 (2000).
  Article CAS PubMed Google Scholar
• Potter, P. M. et al. Construction of adenovirus for high level expression of small RNAs in mammalian cells. Application to a BCL2 ribozyme. Mol. Biotechnol. 15, 105–114 (2000).
  Article CAS PubMed Google Scholar
• Ludwig, A. et al. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. 61, 3053–3061 (2001).
  CAS PubMed Google Scholar
• Jiang, W. G. et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin. Cancer Res. 7, 2555–2562 (2001).
  CAS PubMed Google Scholar
• Cheng, J. et al. Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-MYC specific ribozyme. Cancer Gene Ther. 7, 407–412 (2000).
  Article CAS PubMed Google Scholar
• Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C. & Huber, B. E. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 55, 4808–4812 (1995).
  CAS PubMed Google Scholar
• Hanna, N. N. et al. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 57, 4205–4209 (1997).
  CAS PubMed Google Scholar
• Bridgewater, J. A. et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362–2370 (1995).
  Article CAS PubMed Google Scholar
• Danks, M. K. et al. Overexpression of a rabbit liver carboxylesterase sensitizes human tumour cells to CPT-11. Cancer Res, 58, 20–22 (1998).
  CAS Google Scholar
• Waxman, D. J. et al. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab. Rev. 31, 503–522 (1999).
  Article CAS PubMed Google Scholar
• Sorcher, E. J. et al. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 4, 233–238 (1994).
  Google Scholar
• Topf, N., Worgall, S., Hackett, N. R. & Crystal, R. G. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther. 5, 507–513 (1998).
  Article CAS PubMed Google Scholar
• Gnant, M. F., Puhlmann, M., Alexander, H. R., Jr & Bartlett, D. L. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 59, 3396–3403 (1999).
  CAS PubMed Google Scholar
• Block, A. et al. Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase. Cancer Gene Ther. 7, 438–445 (2000).
  Article CAS PubMed Google Scholar
• Pandha, H. S. et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of ERBB2-directed suicide gene expression. J. Clin. Oncol. 17, 2180–2189 (1999).
  Article CAS PubMed Google Scholar
• Suzuki, S., Tadakuma, T., Asano, T. & Hayakawa, M. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res. 61, 1276–1279 (2001).
  CAS PubMed Google Scholar
• Miyauchi, M. et al. Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells. Int. J. Cancer 91, 723–727 (2001).
  Article CAS PubMed Google Scholar
• Ido, A. et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human α-fetoprotein promoter. Cancer Res. 61, 3016–3021 (2001).
  CAS PubMed Google Scholar
• Morimoto, E., Inase, N., Mlyake, S. & Yoshizawa, Y. Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter. Anticancer Res. 21, 329–331 (2001).
  CAS PubMed Google Scholar
• You, L., Yang, C. T. & Jablons, D. M. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 60, 1009–1013 (2000).
  CAS PubMed Google Scholar
• Xie, X. et al. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum. Gene Ther. 12, 549–561 (2001).
  Article CAS PubMed Google Scholar
• Koeneman, K. S. et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 18, 102–110 (2000).
  Article CAS PubMed Google Scholar
• Chen, R. H. & McCormick, F. Selective targeting to the hyperactive β-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 61, 4445–4449 (2001).
  CAS PubMed Google Scholar
• Hernandez-Alcoceba, R., Pihalja, M., Wicha, M. S. & Clarke, M. F. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum. Gene Ther. 11, 2009–2024 (2000).
  Article CAS PubMed Google Scholar
• Majumdar, A. S. et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther. 8, 568–578 (2001).
  Article CAS PubMed Google Scholar
• Zhang, R., Straus, F. H. & DeGroot, L. J. Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid 11, 115–123 (2001).
  Article CAS PubMed Google Scholar
• Nishino, K. et al. Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc–Max binding motif. Int. J. Cancer 91, 851–856 (2001).
  Article CAS PubMed Google Scholar
• Ueda, K. et al. Enhanced selective gene expression by adenovirus vector using Cre/loxP regulation system for human carcinoembryonic antigen-producing carcinoma. Oncology 59, 255–265 (2000).
  Article CAS PubMed Google Scholar
• Lan, K. H. et al. Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. Gastroenterology 111, 1241–1251 (1996).
  Article CAS PubMed Google Scholar
• Siders, W. M., Halloran, P. J. & Fenton, R. G. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 56, 5638–5646 (1996).
  CAS PubMed Google Scholar
• Chen, J. et al. A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. Cancer Res. 58, 3504–3507 (1998).
  CAS PubMed Google Scholar
• Walton, T. et al. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. Anticancer Res. 18, 1357–1360 (1998).
  CAS PubMed Google Scholar
• Manome, Y. et al. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum. Gene Ther. 9, 1409–1417 (1998).
  Article CAS PubMed Google Scholar
• Gotoh, A. et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol. 160, 220–229 (1998).
  Article CAS PubMed Google Scholar
• McKie, E. A., Graham, D. I. & Brown, S. M. Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector—potential glioblastoma targeting. Gene Ther. 5, 440–450 (1998).
  Article CAS PubMed Google Scholar
• Parr, M. J. et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nature Med. 3, 1145–1149 (1997).
  Article CAS PubMed Google Scholar
• Miyao, Y. et al. Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells. Jpn J. Cancer Res. 88, 678–686 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Ozaki, K. et al. Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC. Hum. Gene Ther. 7, 1483–1490 (1996).
  Article CAS PubMed Google Scholar
• Anderson, L. M., Krotz, S., Weitzman, S. A. & Thimmapaya, B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther. 7, 845–852 (2000).
  Article CAS PubMed Google Scholar